Shareholding disclosure

Kuros Biosciences AG

Collectively declared rate

44.52%

Threshold

Crossed upwards

Timeline

Published

09.12.2015

Transaction

01.12.2015

Voting rights breakdown

Voting rights acquired44.52%
Voting rights sold0%
Below threshold0%

Declared beneficial owners · 5

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

Notice details

CategoryGroup of shareholders
ExchangeXSWX

Notification ID

TBFC800022

Beneficial owner

LSP V Coöperatieve U.A

Declared address

LSP V Coöperatieve U.A., 1071 DV Amsterdam

Each investor has undertaken severally, not jointly, to exchange its shares in Kuros against shares in Cytos as outlined in the combination agreement between Cytos and Kuros dated December 1, 2015, and subject to the terms and conditions set forth therein. At the closing of the transaction, Cytos is expected to issue between 353,006,886 new registered shares (assuming 90% of Kuros shares are exchanged for new Cytos shares) and 392,229,873 new registered shares (assuming 100% of Kuros shares are exchanged for new Cytos shares). Accordingly, the number of shares/voting rights pursuant to the entry in the commercial register will be between 461,022,162 and 500,245,149 at the time the investors will actually become shareholders in Cytos. It is expected that the investors will hold between 9.61% and 10.43% total equity securities and purchase positions post closing. LSP V Management BV is the sole director of LSP V Coöperatieve U.A., a multi-investor fund. LSP Management Group BV is the sole shareholder of LSP V Management BV. Messrs. Kleijwegt, Kuijten, Rothe and Wegter are shareholders of LSP Management Group BV.

These figures aggregate public disclosures. They are not investment advice.

Source: SIX Exchange Regulation

insider24.ch

Never miss a market signal again

Pro alertsEmail and Telegram after publication
Unlimited company trackingUnlimited watchlist with the Pro plan
Monday recapYour stocks' essentials at the open